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 Inhibitors of glutathione reductase (GR) have been synthesized and studied in 
order to reverse an increasing trend in resistance to common malaria treatments.  
Analogues of glutathione (GSH) are being synthesized in order to increase resistance to 
proteolysis, thereby acting as an inhibitor of GR.  Through the use of unnatural amino 
acids, solution-phase synthesis of GSH can be easily performed using modified cysteine 
(Cys) residues.  A modified Cys residue, 2-α-methyl-β-cysteine, has been successfully 
synthesized, and coupling of this residue with the other required residues of GSH, glycine 
(Gly) and glutamic acid (Glu), has the potential to be successfully synthesized in good 
yields, thereby creating a stable GSH analogue. 
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 Amino acids are the building blocks of all peptides and proteins; 20 different 
kinds of amino acids are commonly found in proteins.  All of these natural amino acids 
are considered α-amino acids, meaning that they contain an amino group, a carboxyl 
group, and an organic side chain all bound to the same carbon atom.1  The basic structure 
of an amino acid is detailed in Figure 1. 
 
Figure 1:  General structure of an amino acid 
The R group represents any organic group that can be bonded with the carbon atom, and 
it is the distinguishing characteristic among the amino acids.  The R group can differ in 
size, structure, and electrical charge.  The additional carbons in the R group are labeled 
proceeding outward from the α-carbon as β, γ, δ, ε, and further on depending on the 
number of carbon atoms in the group. With the exception of glycine, which has a 
hydrogen atom as its R group, the amino acids’ α-carbon is bound to four different 
groups.  This characteristic is known as chirality, and the α-carbon is considered to be the 
chiral center.  The spatial arrangement of the groups around the chiral center can be 
oriented in two different ways, meaning that the amino acid has two possible 
enantiomers, or non-superimposable mirror images.  These enantiomers are designated as 
either the L- conformation or D- conformation (Figure 2).  The amino acids found in 
proteins are solely in the L- conformation with very few D- conformational enantiomers 
found in nature.1 
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Figure 2:  L- and D- conformations of alanine 
Amino acids are linked together to form peptides through a condensation reaction.  From 
this reaction, an amide bond is formed between the α-carboxyl group of one amino acid 
and the α-amino group of the target amino acid.1   
 Unlike the natural amino acids, unnatural amino acids (UAAs) are non-
genetically encoded residues that are usually chemically synthesized.  They have been 
studied and utilized in many different roles.  UAAs have been used in peptides to create 
peptidomimetics, which are chains meant to mimic the actions of certain peptides; 
foldamers, which mimic a protein’s action of forming secondary structures such as α-
helixes and β-sheets; ligands; enzyme inhibitors, and starting materials in the formation 
of advanced intermediates.  UAAs have been widely used in order to limit 
conformational flexibility and enhance enzymatic stability.  Of particular interest are the 
β-amino acids as they have been shown to be key components of several enzyme 
inhibitors.  β-amino acids have also been used as major components of developmental 
pharmaceuticals.  UAAs are used in a wide variety of marketed drugs, ranging from 
broad-spectrum antibiotics to high blood pressure medications.2  UAAs are also 
incorporated into peptides to increase resistance to proteolysis.  They can also be used in 
peptides in order to stabilize its secondary structure.3  Approximately 15-20 α-amino 
acids are needed in order to form stable secondary structures in solution;4 however, as 
little as four β- or γ-amino acid residues can form a stable secondary structure.5 Peptides 
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that are composed only of β- and γ- amino acids have been shown to have great stability 
towards enzymes that would normally degrade them in vitro.  The β- and γ-peptides 
remain unchanged for 48 hours in the presence of peptidase enzymes while α-peptides are 
degraded in 1 hour under the same conditions.5   UAAs that have a chiral quaternary α-
carbon have been found to be effective enzyme inhibitors.  The stereospecificity about 
the chiral carbon is important to the action of the peptide.  The L-lysine analog has been 
shown to be an effective inhibitor for lysine decarboxylase; however, the D-lysine analog 
did not inhibit lysine decarboxylase.6 
 The seemingly vast importance of UAAs in several different fields of study has 
led to growing research into efficient and novel methods to synthesize UAAs.3  Several 
different methodologies have been developed and utilized in order to prepare unnatural α-
amino acids.  One type of unnatural α-amino acid is an α-methyl amino acid, which can 
be synthesized by nucleophilic ring opening of Bn2N-α-methylserine-β-lactone with 
various organocuprate reagents, which attacks the methylene carbon of β-lactone in order 
to produce good to excellent yields of the α,α-disubstituted α-amino acids.7  Another 
method by which an  α,α-disubstituted α-amino acid can be prepared is by performing a 
Schmidt rearrangement on a variety of β-keto esters.8  A Schmidt rearrangement involves 
the conversion of specific ketones into amides by using the reagent hydrazoic acid in 
order to form a carbon-nitrogen bond between the target ketone and an azide group 
(HN3).  The amide is created and N2 gas is released.9   
 Not only can unnatural α-amino acids be synthesized, but β-amino acids can also 
be prepared.  An enantiomer selective hydrogen atom transfer method has been used to 
synthesis β-amino acids in good yields.10  A Wolff rearrangement performed on N-
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protected α,α-dialkyl amino acids in order to produce homologation of  α,α-disubstituted 
α-amino acids can also be done to produce β-amino acids.11  The Wolff rearrangement 
involves the conversion of an α-diazo-ketone into a ketene with the loss of nitrogen (N2), 
illustrated by Figure 3.12   
 
Figure 3:  Mechanism of the Wolff rearrangement 
Another important rearrangement that is performed in the preparation of UAAs is the 
Curtius rearrangement.  This reaction, detailed in Figure 4, rearranges an acyl azide into 
an isocyanate.13 
 
Figure 4:  Mechanism of the Curtius rearrangement 
Through the use of a tandem Wolff and Curtius rearrangement sequence, Masterson has 
shown that β2,2-cysteine and serine analogs can be synthesized.  He has also demonstrated 
that α2,2-serine analogues can be prepared with the Curtius rearrangement being a key 
contributor.  The synthesis of the β3,3-analogues of cysteine and serine also involves the 
use of the Curtius rearrangement on half-ester intermediates in order to form the products 
in good yields.3 
 The use of UAAs in peptides is an increasingly important field of study, with 
glutathione (GSH; Figure 5) being a major peptide involved in the research.   
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Figure 5:  Glutathione (GSH) structure 
GSH, a tripeptide of glutamic acid, cysteine, and glycine, contains a γ-peptide bond that 
is not normally found in most peptide structures.  The γ-peptide bond protects the GSH 
peptide from being hydrolyzed by a variety of peptidases.  GSH is the most abundant 
non-protein thiol found in mammalian cells, where it plays a critical role in several 
cellular functions (Figure 6).  It can act as a coenzyme in order to fulfill amino acid 
transport.  GSH is also involved in metabolism as part of oxidation-reduction reactions.14  
The high reactivity of the thiol group (SH) on the Cys residue of GSH is what leads the 
peptide to have good reactivity in oxidation-reduction reactions and toward nucleophilic 
addition.15  GSH has a protective function also; it is able to react with reactive oxygen 
species (ROS) in order to eliminate them.  The ability of GSH to protect against ROS is 
important since ROS has been linked to diseases such as atherosclerosis, rheumatoid 
arthritis, cancer, and several others. 
 
Figure 6:  Multiple actions of glutathione 
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Literature Review  
 The high interest in GSH research stems from the large role it plays in the cell and 
from the diseases associated with a lack of GSH.  Some of these diseases include HIV, 
hepatitis C, type 2 diabetes, ulcerative colitis, and many more.14  GSH is also an 
important peptide to study due to its ability to form disulfide bonds through the reactive 
thiol group of its Cys residue.  Several natural proteins and peptides, such as hormones, 
enzymes, growth factors, toxins, and immunoglobulins, contain disulfide bonds in their 
structures.16  Efforts have been made in order to obtain analogus of natural peptides with 
cyclic disulfide structures in order to improve their therapeutical potential by slowing the 
breakdown of the peptide.17 
 The reactivity of the thiol group allows two molecules of GSH to form a sulfide 
bond between each other in an oxidation reaction, forming glutathione disulfide (GSSG; 
Figure 7).15   
 
Figure 7:  Glutathione disulfide (GSSG) structure  
This disulfide bond can be broken in a reduction reaction that is catalyzed by the enzyme 
glutathione reductase (GR).  This enzyme uses up nicotinamide adenine dinucleotide 
phosphate (NADPH) in order to reduce GSSG back to two molecules of GSH.  
Glutathione reductase allows the cell to maintain a high ratio of GSH concentration to 
GSSG concentration, which enables the cell to detoxify ROS.  A drop in the 
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[GSH]/[GSSG] ratio negatively affects the cells ability to perform this important 
function.18 
 Glutathione plays an important role in the treatment of malaria in people.  Malaria 
can be caused by the parasite Plasmodium falciparum.  Recently, antimalarial agents 
have been met with resistance from the parasite.  It has been shown that elevated GSH 
content in Plasmodium falciparum infected cells lead to this resistance in treatments.  
When the GSH content of the cell is reduced, the sensitivity of the cell to the malarial 
treatment is increased.   The reasoning behind this observation is that GSH protects the 
Plasmodium falciparum parasite from oxidative damage.  In infected cells, GSH is found 
mainly in its reduced form with very little GSSG present.  The high GSH content is 
dependent of the actions of GR; therefore, research has been geared towards creating 
inhibitors of GR for possible malaria treatments.18 
 Several GSH analogues have already been synthesized and studied.  Replacement 
of the natural L-Glu residue with the D- conformation, N-methyl, and α-methyl-Glu has 
been performed.  Other analogues that have been synthesized include GSH with a 
sulfonamide junction replacing the peptide bond of Glu-Cys, replacement of the Glu γ-
carbon with an NH (uriec analogue) or with an oxygen atom (urethanic analogue), and 
addition of a nitro group (NO) to the thiol group of the Cys residue.15  An analogue of 
GSH where the Cys residue is methyl-protected has also been prepared.19  An 
increasingly important field of study in the GSH analogues are those that involve the 
disulfide bonds that Cys residues can create.  Cacciatore20 synthesized an 8-membered 
disulfide ring analogue of GSH by replacing the Gly residue with another Cys residue.  
The two Cys residues form a disulfide bridge through their thiol groups. Cacciatore also 
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synthesized an 11-membered disulfide ring analogue by replacing the Cys-Gly dipeptide 
with a Cys-Asp-Cys residue.  Analysis of the two disulfide ring analogues showed that 
they do not interact with the enzymes γ-glutamyl-transpeptidase and glutathione 
reductase, suggesting that steric hindrance may not allow the peptides into the active site 
of the enzyme.20 
 The purpose of this project is to create a GSH analogue that, when in its oxidized 
state, the disulfide bond created between the Cys residues will have a high resistance to 
being reduced by certain enzymes such as glutathione reductase.  An analogue of GSH 
will be created from a 2-α-methyl-β-cysteine residue.  We hypothesize that by 
incorporating this residue into a peptide to create a GSH analogue, we will strengthen the 
disulfide bond formed during oxidation, creating a more stable form of GSSG that will 





A. NMR and IR analysis 
 The proton nuclear magnetic resonance (NMR) and carbon NMR spectra were 
obtained at 400 MHz.  Proton decoupled mode was used for the carbon NMR analysis.  
The NMR experiments used a TMS internal standard for CDCl3. Infrared spectra analysis 
was acquired as neat oils using a diamond anvil cell.   
 
B. TLC and flash chromatography conditions  
In order to monitor the reactions, thin layer chromatography (TLC) was used.  For 
TLC analysis, silica gel plates containing a 254 nm fluorescent indicator was used.  
Products on the plates were visualized through the use ultraviolet (UV) light and by 
chemical staining.  The solvent systems used for chromatography analysis are reported as 
volumetric ratios.  Flash chromatography was performed using silica gel 60, 230-400 
mesh. 
  
C. Synthesis of the 2-α-methyl-β-cysteine residue 
Synthesis of the 2-α-methyl-β-cysteine was previously published by Masterson.3  
The synthesis was started with a half ester compound previously synthesized in the lab.  
The half ester was dissolved in 5 mL of tetrahydrofuran (THF) and cooled to -25ºC.  A 
1.01 molar equivalent of triethylamine (Et3N) and 1.05 molar equivalent of methyl 
chloroformate (ClCO2Me) was added dropwise.  The solution was stirred at -25ºC for 2 
hours to give a mixed anhydride product.  The white suspension of the mixed anhydride 
was warmed to 0ºC and 2 molar equivalents of dry diazomethane in diethyl ether (Et2O) 
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was added.  The diazomethane was generated the same day by using the Aldrich Mini 
Diazald Apparatus and the methods used were previous published by Sigma-Aldrich.  
After addition of diazomethane, the solution was stirred in the dark at 0ºC for 12 hours.  
Any excess diazomethane was removed by blowing N2 gas through the solution for 30 
minutes.  The mixture was then diluted with ether and washed with saturated aqueous 
NaHCO3, saturated aqueous NH4Cl, and brine.  The organic layer was then dried over 
anhydrous MgSO4, vacuum filtered, and concentrated under vacuum, giving a crude 
diazoketone product  (Scheme 1).  The product was then purified by column 
chromatography (8:2 hexane/diethyl ether). 
 
 
Scheme 1:  Synthesis of diazoketone intermediate 
 The diazoketone was then dissolved in 10 ml of 3:7 H2O/THF in a 25 ml round-
bottomed flask.  The reaction flask was purged with nitrogen gas; the solution was then 
photolyzed with a Hanovia lamp at 500 W at a distance of 10 cm for 72 hours.  After the 
photolysis reaction, the solution was concentrated under vacuum to remove solvent and 
the pH of the solution was adjusted to 9 using concentrated aqueous ammonia.  The 
solution was then washed with ether.  The pH of the aqueous layer was then lowered to 
pH 2 and extracted three times with ether.  The combined organic layers were washed 
with brine, dried over anhydrous MgSO4, vacuum filtered, and solvent was removed 
under reduced pressure.  The product was allowed to dry under vacuum overnight. 
Stbu Stbu 
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 A Curtis rearrangement on the product was then performed in order to produce 2-
α-methyl-β-cysteine.  The previous product was dissolved in 10 ml of dichloromethane 
(CH2Cl2) in a 50 ml round-bottomed flask with a magnetic stir bar.  A 1.02 molar 
equivalent of diphenyl phosphoryl azide (DPPA) and 2.1 molar equivalent of Et3N was 
added and brought to reflux solvent for 1.5 hours.  A 1.39 molar equivalent of p-
methoxybenzyl alcohol (PMB-OH) was added.  The solution was brought to reflux 
solvent for 12 hours, after which the solution was concentrated under vacuum and 




Scheme 2:  Conversion of diazoketone into 2-α-methyl-β-cysteine 
 
D. Coupling of Cysteine and Glycine 
The solution-phase synthesis of GSH using a different Cys residue was previously 
published by Masterson.19 The first step of the synthesis of the glutathione analogue 
(Scheme 3) was a coupling reaction between glycine and the cysteine residue.  2-α-
methyl-β-cysteine (51.7 mg) was mixed with a 1.2 molar equivalent (23.5 mg) of glycine 
ethyl ester hydrochloride and dissolved in dry dichloromethane (CH2Cl2, 0.5 mL).  A 3 
molar equivalent (75 µL) of dry diisopropylethylamine (DIPEA) was then added.  The 
solution was cooled to 0ºC in an ice water bath.  Once cooled, a 1.1 molar equivalent 
(71.8 mg) of bromotripyrrolidinophosphonium hexafluorophosphate (PyBroP) was added 
Stbu Stbu 
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with stirring.  The solution was kept at 0ºC and stirred for 1 hour, after which the cooling 
bath was removed and the solution was allowed to stir at room temperature for 18 hours.  
Completion of the reaction was determined using TLC in 1:1 hexane/ethyl acetate solvent 
and stained using ceric ammonium molybdate (CAM) staining.  The solution was 
concentrated in a stream of N2 gas and purified using flash chromatography in 1:1 
hexane/ethyl acetate solvent.  Solvent was removed under reduced pressure, and the 
product was dried overnight under vacuum.  The N-Moz-protected dipeptide product 
(Compound 2) was isolated as a viscous oil, and percent yield was determined.  Proton 
and carbon NMR, IR spectra were obtaine. The optical rotation of the product was 
determined using ethanol as solvent and dilution to a concentration of 1.00 (10.0 mg/ml).  




Scheme 3: Coupling of 2-α-methyl-β-cysteine with glycine residue 
  
E. Deprotection of the N-terminus of the dipeptide 
The next step of the synthesis (Scheme 4) involved the deprotection of the amino-
terminal of the cysteine residue.  The N-Moz-protected dipeptide (22.5 mg) was dissolved 
in dry CH2Cl2, and 50 µL of thioanisole was added followed by 0.30 mL of 





1 hour, and reaction completion was determined by TLC using 1:1 hexane/ethyl acetate 
solvent.  The volatile components were then blown off using N2 gas.  The resulting 
residue was mixed with 2 mL of distilled water and placed in a separatory funnel. The 
aqueous layer was washed three times with ether in order to remove the thioanisole, and 
then the solution was adjusted to pH 8 by adding a drop of concentrated aqueous 
ammonia.  The aqueous layer was extracted three times with CH2Cl2.  The combined 
organic layers were dried over anhydrous MgSO4 and vacuum filtered.  Solvent was 
removed under reduced pressure, and the product (Compound 3) was dried under vacuum 
overnight.  The percent yield was determined, as was proton and carbon NMR and IR 
spectra.  The optical rotation was determined using chloroform as solvent at a 
concentration of 1.00. A small amount was set aside for HR-MS. 
 
 
Scheme 4:  Removal of the Moz protecting group from the Gly-Cys dipeptide 
  
F. Coupling of Glutamic acid to the dipeptide 
A second coupling reaction (Scheme 5) was then performed. The dipeptide 
product obtained from the previous step was mixed with a 1.5 molar equivalent of N-
Boc-L-glutamic acid 1-tert-butyl ester and dissolved in dry CH2Cl2.  A 3 molar 
equivalent of DIPEA was added to the solution.  The solution was then cooled to 0ºC in 





solution was stirred at 0ºC for 1 hour, after which the cooling bath was removed and the 
solution was stirred for 24 hours at room temperature.  Reaction completion was 
determined using TLC (1:1 hexane/ethyl acetate).  The solution was concentrated under 
vacuum and purified using flash chromatography (1:1 hexane/ethyl acetate). 
 
Scheme 5:  Coupling of glutamic acid to the Gly-Cys dipeptide 
  
G. Deprotection of the Glycine residue 
Next, the ester on the glycine residue was reduced to a carboxcylic acid (Scheme 
6).  The tripeptide was dissolved in 22 mL of THF, which was then followed by addition 
of 7.4 mL of water.  The solution was stirred and cooled to 0ºC in an ice water bath.  A 
2.0 molar equivalent of lithium hydroxoide was added with stirring and dissolved with 15 
minutes.  The reaction was allowed to sit for 1 hour, after which reaction completion was 
determined by TLC (1:1 hexane/ethyl acetate).  Upon completion, 4.6 mL of 1 M 
aqueous NaHSO4 was added to acidify the reaction to pH 1.  The reaction was 
immediately extracted three times with ether, and the combined ether fractions were dried 
over anhydrous MgSO4.  The product was vacuum filtered and the solvent was removed 
under reduced pressure. 
  
H.  Removal of the Boc protecting group from Glu residue 
The Boc protection group was removed (Scheme 6) by dissolving the tripeptide in 







sit for 4 hours, and then it was concentrated in a stream of dry N2.  Dry ether was added 
to the solution, which caused a precipitate to form.  The solid was ground into the ether to 
triturate it, after which the ether layer was decanted.  The solid product was washed with 
ether twice and then dried under reduced pressure.  
 
 
Scheme 6: Expected deprotection reaction of the Gly and Glu residues 
  
I. Removal of tert-butyl group from the sulfur atom 
Next, the tert-butyl protection group on the sulfur was removed (Scheme 7) by 
dissolving the tripeptide from the previous step in 6 mL of TFA, after which 200 µL of 
anhydrous anisole was added, followed by a 2.0 molar equivalent of mercury (II) acetate.  
After 3 hours, solvent was removed in a stream of dry N2 and then reduced further under 
reduced pressure.  The resulting residue was mixed with dry ether, causing a 
thiomercurial intermediate to precipitate.  The solution was centrifuged and the yellow 
supernatant was decanted.  The solid was washed with ether three times in a similar 
fashion until the washes were colorless.  The solid was carefully dried with a gentle 
stream of N2.  The resulting powder was mixed with 25 mL of water, and hydrogen 
sulfide was bubbled through the mixture for 30 minutes with stirring, which formed a 
black precipitate of HgS.  The reaction mixture was purged with N2 for 30 minutes in 
order to remove any residual H2S and centrifuged.  The supernatant was decanted, and 
the solid was extracted once with water and centrifuged.  A 0.1 µm inorganic membrane 
Compound 4 Compound 5 
Stbu 
LiOH, THF, H2O 50% TFA, CH2Cl2 
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was used to filter the combined aqueous layers.  The solvent was removed under reduced 
pressure at room temperature.  The resulting foam was dissolved in methanol, 
concentration to a volume of 0.5 mL, and dry ether was added in order to precipitate the 
product.  The solvent was decanted, and the solid was dried under high vacuum 
overnight.  
 
Scheme 7:  Expected removal reaction of tert-butyl group from the sulfur atom 
  
J. Formation of the disulfide bond 
In order to form the disulfide bond (Scheme 8), the tripeptide from the previous 
step was dissolved in 10 mL of water, followed by addition of concentrated aqueous 
ammonia in order to adjust the pH to 8.  Oxygen was then bubbled through the solution 
with stirring for 16 hours.  Volatile components were removed under reduced pressure at 
room temperature.  The resulting foam was dissolved in 0.5 mL of methanol, followed by 
3 mL of ether in order to precipitate the product. The solvent was decanted and the solid 









i) Hg(OAc)2, TFA 
NH4OH, HsO(pH 8.0), O2 
ii) H2S/ H2O 
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Data 
 The dipeptide product from Scheme 3 was obtained at a yield of 61%.  Optical 
rotation was tested using chloroform as the solvent, at the product was found to rotate 
plane polarized light at +1.05º. 
 














The deprotection reaction (Scheme 4) gave a product yield of 88%.  The compound 
rotated plane polarized light at -11.33º in chloroform as solvent. 
 















 The coupling of glycine to the 2-α-methyl-β-cysteine (Scheme 3) can be 
successfully performed at yields of 60% and higher.  Work by Masterson has shown that 
using PyBroP as the coupling agent increases the percent yields of this step as opposed to 
using N,N-dicyclohexylcarbodiimide (DCC), which usually produces yields of 
approximately 52%.19  The yield of this type of coupling reaction has been show to 
potentially be as high as 84%19; however, issues with the purification using flash 
chromatography lowered the yield from Scheme 3.  A 1 inch diameter column was first 
used, but the column was too large for the product to travel through the silica gel; 
therefore, product was lost and the step had to be repeated.  By using a column with a 
diameter of approximately 1 cm, the product could travel through the gel and be 
collected.  Proton NMR (Spectrum 1) confirmed the presence and purity of the product.  
The ability of the product to rotation plane polarized light around its chiral center was 
tested.  The presence of the Moz protecting group should hinder the ability of Compound 
2 to have an optical rotation, which was observed with a calculated [α] of +1.05º.  IR 
spectrum of the compound showed the Moz protecting group present at 840 cm-1, the 
amide bond present in the 1650-1720 cm-1 range, and the ester at 1719 cm-1.  The α-
methyl group produces a stretch at 2960 cm-1. 
 Removal of the Moz was performed at high yields (88%) using the procedures 
previously published by Masterson.19  The removal of the protecting group while 
retaining the integrity of the dipeptide was observed using 1H-NMR and 13C-NMR 
(Spectrum 4 and 5).  The absence of the aromatic and ester peaks from the Moz group, 
along with the retention of all other peaks from the peptide, indicated that Compound 3 
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was successfully produced.  In the 1H-NMR spectrum, the absence of peaks at 2.0 ppm, 
3.7 ppm, and 6.8 ppm indicated the loss of the Moz group.  In the 13C-NMR spectrum, 
peaks were lost at 55 ppm, 59 ppm, 65 ppm, 105 ppm, 128 ppm, and 157 ppm, also 
indicating the loss of the aromatic ring and ester group which makes up the Moz group.  
IR spectrum also indicates the loss of the Moz group, with stretching present from 820-
840 cm-1, which was seen in the protected dipeptide. All the notable peaks mentioned 
with the protected dipeptide were retained after the Moz group was removed.  With the 
Moz protecting group removed, Compound 3 should have a noticeable optical rotation, 
which was observed when tested with a calculated [α] value of -11.33º. 
 The coupling reaction of glutamic acid and the dipeptide (Scheme 5), has been 
performed on a small scale; however, the mass of product obtained was too low to 
accurately measure and report 1H-NMR, 13C-NMR, IR, or optical rotation.  Measures are 
currently being taken in order to produce more 2-α-methyl-β-cysteine in order to continue 
with the synthesis and obtain a higher yield of the tripeptide produce (Compound 4).   
 As of the writing of this paper, Schemes 6, 7, and 8 have not been performed, and 
Scheme 5 has not been perform to adequate yields in order to collect proper data.  
However, these reactions are known to work and be reproducible.19  Based on the 
projections of this project and the published literature, a glutathione analogue using 2-α-
methyl-β-cysteine can been successfully synthesized using a seven step process, with 
formation of glutathione disulfide able to be performed at high yields (86%).19 
 The fully deprotected tripeptide and its disulfide form will be produced in the 
future.  Once a substantial amount of glutathione disulfide has been synthesized, 
experiments testing the resistance of glutathione disulfide analogue to enzymatic 
23 
degradation will be performed.  The results of the enzymatic degrading will show 
whether 2-α-methyl-β-cysteine incorporated into a glutathione peptide helps stabilize the 
disulfide structure of the peptide, allowing it to resist degradation and act as a glutathione 
reductase inhibitor. The ability to successfully incorporate the unnatural 2-α-methyl-β-
cysteine amino acid into an analogue of glutathione will potentially cause this desired 
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